Carcinoma of the male breast: A review of 200 cases.
dc.contributor.author | Ribeiro, G | |
dc.date.accessioned | 2011-07-22T12:04:15Z | |
dc.date.available | 2011-07-22T12:04:15Z | |
dc.date.issued | 1977-06 | |
dc.identifier.citation | Carcinoma of the male breast: A review of 200 cases. 1977, 64 (6):381-3 Br J Surg | en |
dc.identifier.issn | 0007-1323 | |
dc.identifier.pmid | 68794 | |
dc.identifier.doi | 10.1002/bjs.1800640602 | |
dc.identifier.uri | http://hdl.handle.net/10541/136592 | |
dc.description.abstract | Two hundred cases of male breast carcinoma were treated at the Christie Hospital, Manchester, between 1942 and 1971. The survival rate of the group following curative treatment is presented; the response to palliative treatment is also discussed. The survival rate was particularly good for stage I cases, with 79 per cent surviving for 5 years and 56-3 per cent surviving for 10 years. However, the later stages did less well, particularly when compared with female patients of the same age and stage. With such a rare disease it would be of help to centralize the treatment of these patients as much as possible. | |
dc.language.iso | en | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Mastectomy | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Metastasis | |
dc.subject.mesh | Neoplasm Recurrence, Local | |
dc.subject.mesh | Palliative Care | |
dc.subject.mesh | Time Factors | |
dc.title | Carcinoma of the male breast: A review of 200 cases. | en |
dc.type | Article | en |
dc.identifier.journal | The British Journal of Surgery | en |
html.description.abstract | Two hundred cases of male breast carcinoma were treated at the Christie Hospital, Manchester, between 1942 and 1971. The survival rate of the group following curative treatment is presented; the response to palliative treatment is also discussed. The survival rate was particularly good for stage I cases, with 79 per cent surviving for 5 years and 56-3 per cent surviving for 10 years. However, the later stages did less well, particularly when compared with female patients of the same age and stage. With such a rare disease it would be of help to centralize the treatment of these patients as much as possible. |